Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ben Lamm
AddedMar 31, 2024
UpdatedJun 28, 2026
Ben Lamm

Ben Lamm

Board Member, Hypergiant

CrunchbaseLinkedIn

Ben Lamm's Career

Hypergiant
Hypergiant

Austin, TX, US

Board Member· Board
Colossal Biosciences
Colossal Biosciences

Austin, TX, US

Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ben Lamm's Career

Hypergiant
Hypergiant
Angel1852018Austin, TX, US
Board Member· Board

Leadership at Hypergiant

Mike BetzerMike BetzerBoard Member
Sangeeta MudnalSangeeta MudnalBoard Member
Brian BeardBrian BeardBoard Member
John FremontJohn FremontCo-Founder
Chris DaveyChris DaveyBoard Member
Colossal Biosciences
Colossal Biosciences
Series A$235.5M1652021Austin, TX, US
Founder & CEO· C-Suite · Management

Recent news

Colossal Labs will release the sounds of dire wolves howling ‘later this year,’ founder saysTechCrunch · 2025
Making more mammoths with Ben Lamm from ColossalTechCrunch · 2023

Leadership at Colossal Biosciences

David L. SzekeresDavid L. SzekeresBoard Member

Similar to Colossal Biosciences

Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
eGenesiseGenesisCambridge, MA, USGene Editing, Organsest. 2015eGenesisCambridge, MA, US · est. 2015

eGenesis: Revolutionizing transplantation with a gene editing platform for human-compatible organs.

Series C · $265M105
Altos LabsAltos LabsRedwood City, CA, USCell Therapiesest. 2021Altos LabsRedwood City, CA, US · est. 2021

Altos Labs, Inc.: An American biotech firm pioneering life extension therapies via specialized cell therapies since 2022.

Series A · $3B500
Sylvatica BiotechSylvatica BiotechNorth Charleston, SC, USDevelopment, ResearchSylvatica BiotechNorth Charleston, SC, US

Sylvatica Biotech, Inc.: Pioneering commercial physical and biological research since 2015.

Seed · $12.6M7

Ben Lamm's Co-Investors

Adam ZeplainAdam ZeplainCo-invested · Prima SeedChris RhodesChris RhodesCo-invested · Hypergiant Sensory Sciences AngelChris RhodesChris RhodesCo-invested · Hypergiant Sensory Sciences AngelAndrew BuseyAndrew BuseyCo-invested · ClearBlade Series AJim SchneiderJim SchneiderCo-invested · ClearBlade Series AJan LindelowJan LindelowCo-invested · ClearBlade Series ATim RingelTim RingelCo-invested · SpaceX Series HJason StoryJason StoryCo-invested · Kazoo Seed

Ben Lamm's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Ben Lamm

Dave CoppsDave CoppsCo-Founder & CEO · WorldsMichael RobertsMichael RobertsCo-Founder · SocialMatters.aiFelipe LamounierFelipe LamounierCo-Founder · Hyperplane AIElliot TurnerElliot TurnerCo-Founder · HyperiaBogdan PreduscaBogdan PreduscaCo-Founder · getfittter